Ryan Longmore, DO
Cardiovascular Disease · Pocatello, IDNPI 1285884213
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,674 of the $60,276 with a category attached, or 75.8%. E.r. Squibb & Sons, L.L.C. accounts for 92.1% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $29,692 and has fallen 62.5% since, to $11,127 in 2025. Among cardiovascular disease clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $256.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$55K
- Abbott$2K
- Boston Scientific$951
- Pfizer$272
- Amgen$200
- Novartis$175
- plus $916 from 15 others
What the payments were for
- Consulting fees$1,5002%
- Speaking & faculty fees$45,67476%
- Travel & lodging$8,42114%
- Food & beverage$4,6818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 54 | $55,485 |
| Abbott | 37 | $2,278 |
| Boston Scientific | 84 | $951 |
| Pfizer | 14 | $272 |
| Amgen | 9 | $200 |
| Novartis | 9 | $175 |
| Impulse Dynamics (USA) Inc. | 3 | $160 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $140 |
| Bridgebio Pharma, Inc. | 3 | $121 |
| Heartflow, Inc. | 1 | $94 |
| Medtronic(2 entities) | 2 | $86 |
| Edwards Lifesciences | 1 | $62 |
| ZOLL Respicardia, Inc. | 2 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $47 |
| Esperion Therapeutics, Inc. | 1 | $47 |
| AstraZeneca | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Cvrx, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,276 in reported general payments places this provider in the 90th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 33 | $27,140 |
| FarxigaDapagliflozin Propanediol | 14 | $9,725 |
| Atorvastatin Calcium | 90 | $660 |
| Metoprolol Succinate | 60 | $517 |
| Potassium Chloride | 21 | $319 |
| Carvedilol | 45 | $271 |
| Spironolactone | 22 | $229 |
| Ezetimibe | 13 | $204 |
| Rosuvastatin Calcium | 23 | $137 |
| Furosemide | 45 | $133 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $120 |
| Losartan Potassium | 26 | $110 |
| Lisinopril | 17 | $106 |
| ClopidogrelClopidogrel Bisulfate | 14 | $95 |
| Amlodipine Besylate | 25 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $272 | $27,14033 claims |
| AstraZenecaFarxiga | $30 | $9,72514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 59 cardiovascular disease providers in Idaho.
Other cardiovascular disease in Pocatello
- Jacob DelarosaPocatello$226K
- Benjamin CallPocatello$5K
- Fernando GrigeraPocatello$4K
- Jarrah AlfadhliPocatello$899
- Chandana ShekarPocatello$573
- David HinchmanBoise$324K
- David LaxsonKetchum$135K
- Robyn BrydeBoise$27K
- Ronald FritzCoeur D Alene$17K
- Douglas BlankIdaho Falls$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.